Presentations and Interviews

  Presentation Media Date

ACD856 – a novel positive allosteric modulator of Trk-receptors in clinical development for the treatment of Alzheimer’s disease; Scientific presentation at AAIC, July 26-30, 2021

July 29, 2021

Om AlzeCures uppkomst och utveckling – Ett embryo som kan bli något stort – med Bengt Winblad, professor, senior vid Karolinska Institutet.

June 11, 2021

Om Alzstatin och läkemedel vid Alzheimers sjukdom – med Bengt Winblad, professor, senior vid Karolinska Institutet.

June 11, 2021

Om att drabbas av Alzheimers sjukdom, diagnostik, vården idag samt framtida behov – med Bengt Winblad, professor, senior vid Karolinska Institutet.

June 11, 2021

Negative Allosteric Modulators of TrkA for the Treatment of Pain – Scientific presentation at the IASP conference on pain, June 2021

June 11, 2021

ACD440 – A Novel TRPV1 Antagonist for the Topical Treatment in Neuropathic Pain – Scientific presentation at the IASP conference on pain, June 2021

June 9, 2021

Alzecure: CEO Martin Jönsson present at Redeye Growth Day

June 7, 2021

CEO Martin Jönsson after the company’s annual meeting

May 17, 2021

TrkA- NAM – Project in osteoarthritis & other severe pain conditions by Head of Discovery & Research Pontus Forsell, May 11, 2021

May 11, 2021

ACD 440 – A novel VR1 antagonist for neuropathic pain by CSO Johan Sandin, May 11, 2021

May 11, 2021

Chronic Pain – a high unmet medical need by CMO Märta Segerdahl, May 11, 2021

May 11, 2021

Company overview and goals by CEO Martin Jönsson, May 11, 2021

May 11, 2021

Update on Progress in the Painless Platform, May 11, 2021

May 11, 2021

Alzecure: Interview with CEO Martin Jönsson and CSO Johan Sandin (video)

April 20, 2021

Alzecure: Intervju med vd Martin Jönsson (video)

March 1, 2021

Interview with Martin Jönsson CEO in Aktiespararna’s analysis guide

February 8, 2021

Improving Quality of Life for People with Neurodegenerative Diseases – Stockholm Researchers and Health Tech Companies

January 14, 2021

CEO Martin Jönsson presentation, Aktiedagen Lund

January 27, 2021

Interview with Johan Sandin (CSO) in Aktiespararna’s analysis guide

January 22, 2021

Alzecure: CEO Martin Jönsson presents at Redeye Life Science Day 2020

December 1, 2020

Scientific presentation on the NeuroRestore® candidate ACD856 presented at the CTAD conference

November 4-7, 2020

Scientific presentation on Alzstatin presented at the CTAD conference

November 4-7, 2020

Scientific and market update with professor Henrik Zetterberg on Alzheimer’s disease, bio-markers, potential future treatments, including Alzstatin and AlzeCure

September 30, 2020

AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish)

September 8, 2020

AlzeCure Science & Market update about Alzheimer’s diseas and NeuroRestore (Swedish)

September 1, 2020

Welcome to AlzeCure … Introduction film about the company (Swedish) – 1 minute

CEO presentation at the annual meeting (Swedish)

May 20, 2021

Scientific presentation about ACD856, a positive modulator of neurotrophin signaling reverses scopolamine- or age-induced cognitive deficits

April 2-5, 2020

Get to know AlzeCure’s CEO Martin Jönsson – Redeye interview (Swedish)

March 19, 2020

AlzeCure presentation with CEO Martin Jönsson at Aktiespararna (Swedish)

March 16, 2020

About the Alzstatin® project Disease modifying treatment of Alzheimer’s disease

About Alzheimers disease

February 27, 2018

About the project NeuroRestore®, symptomatic treatment of cognitive disorders such as in Alzheimer’s disease

February 27, 2018